85 related articles for article (PubMed ID: 16480942)
21. Host cell responses induced by hepatitis C virus binding.
Fang X; Zeisel MB; Wilpert J; Gissler B; Thimme R; Kreutz C; Maiwald T; Timmer J; Kern WV; Donauer J; Geyer M; Walz G; Depla E; von Weizsäcker F; Blum HE; Baumert TF
Hepatology; 2006 Jun; 43(6):1326-36. PubMed ID: 16729312
[TBL] [Abstract][Full Text] [Related]
22. Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents.
Nishimura G; Ikeda M; Mori K; Nakazawa T; Ariumi Y; Dansako H; Kato N
Antiviral Res; 2009 Apr; 82(1):42-50. PubMed ID: 19428594
[TBL] [Abstract][Full Text] [Related]
23. A hepatitis C virus xenograft mouse efficacy model.
Zhu Q; Weiner AJ
Methods Mol Biol; 2009; 511():323-31. PubMed ID: 19347304
[TBL] [Abstract][Full Text] [Related]
24. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.
Gottwein JM; Bukh J
Adv Virus Res; 2008; 71():51-133. PubMed ID: 18585527
[TBL] [Abstract][Full Text] [Related]
25. HCV research and anti-HCV drug discovery: toward the next generation.
Wakita T
Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
[TBL] [Abstract][Full Text] [Related]
26. Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins.
Ishii K; Murakami K; Hmwe SS; Zhang B; Li J; Shirakura M; Morikawa K; Suzuki R; Miyamura T; Wakita T; Suzuki T
Biochem Biophys Res Commun; 2008 Jul; 371(3):446-50. PubMed ID: 18445476
[TBL] [Abstract][Full Text] [Related]
27. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
[TBL] [Abstract][Full Text] [Related]
28. Anti-HCV bioactivity of pseudoguaianolides from Parthenium hispitum.
Hu JF; Patel R; Li B; Garo E; Hough GW; Goering MG; Yoo HD; O'neil-Johnson M; Eldridge GR
J Nat Prod; 2007 Apr; 70(4):604-7. PubMed ID: 17291045
[TBL] [Abstract][Full Text] [Related]
29. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
Qi X; Bae A; Liu S; Yang H; Sun SC; Harris J; Delaney W; Miller M; Mo H
Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
[TBL] [Abstract][Full Text] [Related]
30. Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells.
Fillebeen C; Muckenthaler M; Andriopoulos B; Bisaillon M; Mounir Z; Hentze MW; Koromilas AE; Pantopoulos K
J Hepatol; 2007 Jul; 47(1):12-22. PubMed ID: 17399844
[TBL] [Abstract][Full Text] [Related]
31. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication.
Itsui Y; Sakamoto N; Kurosaki M; Kanazawa N; Tanabe Y; Koyama T; Takeda Y; Nakagawa M; Kakinuma S; Sekine Y; Maekawa S; Enomoto N; Watanabe M
J Viral Hepat; 2006 Oct; 13(10):690-700. PubMed ID: 16970601
[TBL] [Abstract][Full Text] [Related]
32. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus NS2 protein activates cellular cyclic AMP-dependent pathways.
Kim KM; Kwon SN; Kang JI; Lee SH; Jang SK; Ahn BY; Kim YK
Biochem Biophys Res Commun; 2007 May; 356(4):948-54. PubMed ID: 17395159
[TBL] [Abstract][Full Text] [Related]
34. Impact of steroids on hepatitis C virus replication in vivo and in vitro.
Henry SD; Metselaar HJ; Van Dijck J; Tilanus HW; Van Der Laan LJ
Ann N Y Acad Sci; 2007 Sep; 1110():439-47. PubMed ID: 17911459
[TBL] [Abstract][Full Text] [Related]
35. Dynamic behavior of hepatitis C virus quasispecies in a long-term culture of the three-dimensional radial-flow bioreactor system.
Murakami K; Inoue Y; Hmwe SS; Omata K; Hongo T; Ishii K; Yoshizaki S; Aizaki H; Matsuura T; Shoji I; Miyamura T; Suzuki T
J Virol Methods; 2008 Mar; 148(1-2):174-81. PubMed ID: 18164425
[TBL] [Abstract][Full Text] [Related]
36. Positional effects and strand preference of RNA interference against hepatitis C virus target sequences.
Smith RM; Smolic R; Volarevic M; Wu GY
J Viral Hepat; 2007 Mar; 14(3):194-212. PubMed ID: 17305886
[TBL] [Abstract][Full Text] [Related]
37. Effect of hepatitis C virus core shadow protein expressed in human hepatoma cell line on human gene expression profiles.
Dou J; Liu P; Wang J; Zhang X
J Gastroenterol Hepatol; 2006 Dec; 21(12):1794-800. PubMed ID: 17074016
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of chemical labeling strategies for monitoring HCV RNA using vibrational microscopy.
Noestheden M; Hu Q; Tonary AM; Tay LL; Pezacki JP
Org Biomol Chem; 2007 Aug; 5(15):2380-9. PubMed ID: 17637957
[TBL] [Abstract][Full Text] [Related]
39. TAT peptides mediated small interfering RNA delivery to Huh-7 cells and efficiently inhibited hepatitis C virus RNA replication.
Meng S; Wei B; Xu R; Zhang K; Wang L; Zhang R; Li J
Intervirology; 2009; 52(3):135-40. PubMed ID: 19478527
[TBL] [Abstract][Full Text] [Related]
40. Molecular virology of the hepatitis C virus: implication for novel therapies.
Glenn JS
Clin Liver Dis; 2005 Aug; 9(3):353-69, v. PubMed ID: 16023970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
